The expression of PD-L1 is promoted by EMT in carcinoma cells, and tumors that express higher EMT scores have been found to respond better to antibodies targeting CTL-A4, PD1, and PD-L1, as well as express increased levels of other immune checkpoint markers (35). This evidence concerns the gene CD274 and carcinoma.